dc.contributor.author
Lebedin, Mikhail
dc.contributor.author
García, Clara Vázquez
dc.contributor.author
Spatt, Lisa
dc.contributor.author
Ratswohl, Christoph
dc.contributor.author
Thibeault, Charlotte
dc.contributor.author
Ostendorf, Lennard
dc.contributor.author
Alexander, Tobias
dc.contributor.author
Paul, Friedemann
dc.contributor.author
Sander, Leif Erik
dc.contributor.author
Kurth, Florian
dc.contributor.author
de la Rosa, Kathrin
dc.date.accessioned
2025-12-09T10:55:18Z
dc.date.available
2025-12-09T10:55:18Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/50739
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-50466
dc.description.abstract
Diverse autoantibodies were suggested to contribute to severe outcomes of COVID-19, but their functional implications are largely unclear. ACE2, the SARS-CoV-2 receptor and a key regulator of blood pressure, was described to be one of many targets of autoantibodies in COVID-19. ACE2 in its soluble form (sACE2) is highly elevated in the blood of critically ill patients, raising the question of whether sACE2:spike complexes induce ACE2 reactivity. Screening 247 COVID-19 patients, we observed elevated sACE2 and anti-ACE2 IgG that were poorly correlated. Interestingly, levels of IgGs recognizing ACE2, IFN alpha 2, and CD26 strongly correlated in severe COVID-19, with 15% of sera showing polyreactivity versus 4.1% exhibiting target-directed autoimmunity. Promiscuous autoantibodies failed to impair the activity of ACE2 and IFN alpha 2, while only specific anti-IFN alpha 2 IgG compromised cytokine function. Our study suggests that the detection of autoantibodies in COVID-19 is often attributed to a promiscuous reactivity, potentially misinterpreted as target-specific autoimmunity with functional impact.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Autoantibodies
en
dc.subject
Autoimmunity
en
dc.subject
Autoreactivity
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Discriminating promiscuous from target‐specific autoantibodies in COVID‐19
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1002/eji.202250210
dcterms.bibliographicCitation.journaltitle
European Journal of Immunology
dcterms.bibliographicCitation.number
5
dcterms.bibliographicCitation.originalpublishername
Wiley
dcterms.bibliographicCitation.volume
53
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
36856018
dcterms.isPartOf.issn
0014-2980
dcterms.isPartOf.eissn
1521-4141